Population health is an increasingly clear and important priority for the health and care system and is key in addressing health inequalities. This is clear in the NHS Long Term Plan, in the 2022 Health and Care Act, and in the current and likely future policy landscape. A population health-led approach to health and care aims to improve physical and mental health outcomes, promote wellbeing and reduce health inequalities across an entire population. Whether you’re working in an integrated care system (ICS), primary care network, a national body, community group, or you’re someone with lived experience it is likely that you have been thinking about your own role in population health and how best you can help to improve the health and care of the people in your local area. This event will bring together those working in the NHS, public health, local authorities, the voluntary, community and social enterprise sector, and local communities to consider how best they can join the dots between work that is already under way and how to support others in their efforts to improve population health.

Read on kingsfund.org.uk

The pharma sector is a major contributor to global greenhouse gas emissions, with emission intensity being approximately 55 percent higher than that of the automotive sector. Global leaders in the pharmaceutical industry are prioritizing the elimination of harmful greenhouse gas emissions to limit global temperature to the 1.5-degree rise, as proposed in the Paris Climate Agreement of December 2015. The need to improve CO2 footprint in the pharmaceutical cold chain is now more than ever. 

In this webinar, Berlinger and South Pole discuss the impact of climate actions on the pharma cold chain market, the Berlinger and South Pole climate journey as well as how sustainability can add value to the respective business case. Berlinger argues that improving the ROI whilst reducing CO2 emissions in the pharmaceutical cold chain are not mutually exclusive.

Read on xtalks.dryfta.com

The pharma sector is a major contributor to global greenhouse gas emissions, with emission intensity being approximately 55 percent higher than that of the automotive sector. Global leaders in the pharmaceutical industry are prioritizing the elimination of harmful greenhouse gas emissions to limit global temperature to the 1.5-degree rise, as proposed in the Paris Climate Agreement of December 2015. The need to improve CO2 footprint in the pharmaceutical cold chain is now more than ever. From ambition to action, Berlinger has turned the challenge of high emissions in cold chain logistics into an opportunity for innovation. The company has developed an entirely new smart monitoring ecosystem “SmartSystem” meeting the various challenges of the industry among others real-time coverage, costs and sustainability. The basis for innovation is a baseline carbon footprint analysis of the Berlinger product portfolio. The project that was successfully completed with the renowned sustainability advisory South Pole in 2021 significantly impacted the innovation process of SmartSystem - in terms of hardware platform and respective business models - and resulted in the awarding of the Climate Neutral Product Label in 2022. In this webinar, Berlinger and South Pole discuss the impact of climate actions on the pharma cold chain market, the Berlinger and South Pole climate journey as well as how sustainability can add value to the respective business case. Berlinger argues that improving the ROI whilst reducing CO2 emissions in the pharmaceutical cold chain are not mutually exclusive.

Read on xtalks.com

HealthIL is the leading Healthcare Innovation Ecosystem in Israel, aiming to foster technological transformation in healthcare systems, both in Israel and globally. Our Mission is to improve healthcare by bridging the gap between the healthcare system and tech community.

Read on healthilweek.org

The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important.

This year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech, pharma and academia to continue to develop resilient, long-lasting and robust analytical tools to enhance the safety, quality and efficacy of gene therapy products.

Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges.

If you work in quality control, quality assurance, or process development - we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support.

Whether you're working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

How do you retain patients in a complex trial? For clinical research professionals, testing medications and procedures on patient populations who feel unwell and have mobility or logistical challenges can be taxing, physically, mentally and emotionally for patients and their families - disruptive to their everyday lives and to the everyday lives of their families. For many clinical trialists, patient retention and engagement, especially in a complex trial, are challenges that keep them up at night, worrying that valuable patients will not complete the trial. A DCT is proven to improve patient retention, but if it’s a method of conducting research that the trialist hasn’t experienced before, the benefit, value and possibilities when building decentralized trial visits into a protocol, might not be fully realized. There are many procedures that can be completed in the home, and a significant number of those are far more complex than anticipated. From double blinded healthcare professionals delivering IMP, to timed pharmacokinetic blood draws and digitally linked visits, there are so many complex visit types that can be delivered in a DCT.

Read on xtalks.com

Most of all, AAC extends its warm greetings to all Organizing Committee Members, Keynote Speakers, Speakers, Delegates, Exhibitors and students who were a part of Pathology and Oncology Research 2022 and making it a grand success. Allied Academics hosted the joint event of “4th International Conference on Pathology and Oncology Research” which was held during November 28-29, 2022 with the theme “Navigating the future on Pathology and Oncology”. The active support of the Editorial Board Members, Scientists, Researchers, Scholars, and Students in the field of Pathology are the backbone of the conference success.

Read on europathology.alliedacademies.com

With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients' lives.

The 2nd Rare CNS and Neurodevelopmental Drug Development Summit is the definitive industry-dedicated forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.

Tightly focused on industry progress, join stakeholders exploring ASOs, gene therapies and small molecules across autistic syndromes and seizure phenotypes in at this unique drug sponsor conference.

Don't miss out on the industry's definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers, emerging therapeutic targets and translational biology

If you are working towards treatments for rare CNS and neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Time: 8:00 am - 3:50 pm

Save money by reserving next year’s hotel room through RSNA! Reserve early to get the best available pricing and selection at a wide variety of exceptional hotels. We'll assist with all your housing inquiries and concerns, allowing you to enjoy the many benefits of using RSNA as your dedicated travel partner. Keep your educational momentum going and take advantage of virtual access to RSNA 2021 until April 30, 2022. New and current registrants can access educational and scientific content from every subspecialty and visit the Virtual Exhibition all from the comfort of home. Register or upgrade your access today to find endless opportunities to earn CME.

Read on rsna.org

Register for this webinar and learn about using point-of-care testing to transform patient care in general practice and primary care networks.

Read on xtalks.dryfta.com